Additional genetic testing or retesting in patients diagnosed with FH, treated properly still without sufficient required response and result in measured values and clinical symptoms could be recommended. Potential similarities between the patients in their phenotypes or genotypes can be found.
The International Atherosclerosis Society and the European Atherosclerosis Society have recently unveiled updated guidelines on FH and Homozygous FH. The IAS has recently published evidence-informed guidance for implementing best practices in the care of Familial Hypercholesterolaemia (FH). This comprehensive guidance aims to benefit individuals with FH across different countries.
Read the full IAS guidelines HERE.
The EAS has also released an updated consensus statement specifically addressing Homozygous Familial Hypercholesterolaemia (HoFH). This statement provides new treatments and clinical guidance for HoFH. It explains the genetic complexity of HoFH and offers pragmatic recommendations to address inequities in HoFH care worldwide. Read the full EAS guidelines HERE.